Khalili, Azadeh, Karim, Hossein, Goudarzvand, Mahdi, Bayat, Gholamreza (2025). Drug-drug interactions in pharmacotherapy of heart failure: Risk of electrolyte abnormalities. , 28(2), 7-12. doi: 10.48311/mjms.2025.19536
Azadeh Khalili; Hossein Karim; Mahdi Goudarzvand; Gholamreza Bayat. "Drug-drug interactions in pharmacotherapy of heart failure: Risk of electrolyte abnormalities". , 28, 2, 2025, 7-12. doi: 10.48311/mjms.2025.19536
Khalili, Azadeh, Karim, Hossein, Goudarzvand, Mahdi, Bayat, Gholamreza (2025). 'Drug-drug interactions in pharmacotherapy of heart failure: Risk of electrolyte abnormalities', , 28(2), pp. 7-12. doi: 10.48311/mjms.2025.19536
Khalili, Azadeh, Karim, Hossein, Goudarzvand, Mahdi, Bayat, Gholamreza Drug-drug interactions in pharmacotherapy of heart failure: Risk of electrolyte abnormalities. , 2025; 28(2): 7-12. doi: 10.48311/mjms.2025.19536

Drug-drug interactions in pharmacotherapy of heart failure: Risk of electrolyte abnormalities

Pathobiology Reserach
Article 1, Volume 28, Issue 2, 2025, Pages 7-12    PDF (205.39 K)
Document Type: Systematic Review
DOI: 10.48311/mjms.2025.19536
Authors
Azadeh Khalili1; Hossein Karim2; Mahdi Goudarzvand3; Gholamreza Bayat* 1
1Evidence-based Phytotherapy and Complementary Medicine Research Center, Alborz University of Medical Sciences, Karaj, Iran Department of Physiology-Pharmacology-Medical Physics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
2Cardiovascular research center, Alborz University of Medical Sciences, Karaj, IranDepartment of Cardiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
3Department of Physiology-Pharmacology-Medical Physics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
Abstract
Heart failure (HF) is associated with several systemic complications that require combination therapies. Considering the type and clinical manifestations of HF, several types of medications are used to overcome some harmful activated compensatory mechanisms. Angiotensin receptor–neprilysin inhibitors (ARNIs), angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs) and sodium–glucose cotransporter 2 (SGLT2) inhibitors alongside with other classes like diuretics, vasodilators and/or positive inotropic agents constitute the medication basket for patients with heart failure. Polypharmacy with different classes of drugs increases the risk of drug-drug interactions during treatment. One of the main issues in these interactions is the risk of electrolyte abnormalities, especially regarding the potassium level, which would be so threatening. This mini review focused on specific aspects of drug-drug interactions that might occur during treatment and how they can be life-threatening.
Keywords
Heart failure; ARNIs; SGLT2 inhibitors; ARBs; ACEIs; Drug-interaction; Electrolyte abnormalities
References
Statistics
Article View: 93
PDF Download: 86
Statistics
Number of Journals45
Number of Issues2,171
Number of Articles24,674
Article View24,448,482
PDF Download17,555,331